Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Jort Merken: Innovator in Predicting Cardiotoxicity Risk
Introduction
Jort Merken is a notable inventor based in Maastricht, Netherlands. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach has the potential to improve patient outcomes and enhance treatment safety.
Latest Patents
Jort Merken holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting cardiotoxicity risk based on the determination of the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also identifies this set of miRNAs as a biomarker for predicting cardiotoxicity risk in patients receiving anthracyclines chemotherapy. Furthermore, it contemplates a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.
Career Highlights
Throughout his career, Jort Merken has worked with esteemed institutions such as the Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His work has been instrumental in advancing research in the medical field, particularly in oncology and cardiology.
Collaborations
Jort has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to the development and refinement of his innovative research.
Conclusion
Jort Merken's contributions to predicting cardiotoxicity risk in cancer patients represent a significant advancement in medical research. His innovative methods and collaborations highlight the importance of interdisciplinary efforts in improving patient care.